Atrial Fibrillation is the most common cardiac arrhythmia and its prevalence in chronic kidney disease is higher than in the general population. Patients with renal insufficiency have a higher risk of thromboembolic events than patients with normal renal function and this risk increases with worsening renal function. At the same time, the risk of bleeding from anticoagulation therapy is a concern in these patients. This combination of thromboembolism and concomitant bleeding risk creates a challenging clinical situation and treatment of these patients therefore requires careful assessment of the risks and benefits of anticoagulation as renal function deteriorates.
Join Prof John Camm and Prof Phil Aylward to discuss the therapeutic challenge these patients present, review the evidence and provide insights into the management these complex patients.
Tonight | 7pm to 8pm AEST
Professor John Camm is emeritus Professor of Clinical Cardiology at St George’s Hospital Medical School, University of London, UK. He is President and trustee of the Arrhythmia Alliance, and Editor-in-Chief of European Heart Journal – Case Reports and Clinical Cardiology and Editor of several journals including the European Heart Journal. Professor Camm has been involved in the production of numerous guidelines, including the ESC guidelines for the management of atrial fibrillation.
Professor Phil Aylward is a clinical cardiologist with a particular interest in Acute Coronary Syndromes. He is a Professor of Medicine at Flinders University and a Member of the Innovation Centre within SAHMRI Heart Health and leading the development of Education Programmes. He has been involved over two decades in clinical trials and has been a member of a number of International Steering & Executive Committees in Cardiology particularly in areas of Acute Coronary Syndromes, atrial fibrillation and lipid management.
This webinar has been produced by Bayer Australia Limited. Bayer endorses the Medicines Australia Code of Conduct and all activities conducted as part of this meeting must comply with the Code. Some presentations may refer to products or indications not approved in your country. Please refer to the approved Product Information before prescribing. The views and opinions expressed throughout this meeting are those of the speaker and do not necessarily represent the views, policy or position of Bayer.
Bayer Australia Ltd. ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073. PP-XAR-AU-0579-1. July 2020.